Acquisition Adds Complementary, Decreased Cost Merchandise for Dealing with Conditions Associated with Obstructive Sleep Apnea

LITTLETON, Colo., March 01, 2023 (Globe NEWSWIRE) — Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a health-related device and know-how corporation that delivers teaching and a entire line of really powerful proprietary oral appliances for the treatment method of respiration linked snooze conditions, such as delicate-to-reasonable obstructive sleep apnea (OSA) and snoring in grown ups, now introduced it has obtained particular U.S. and worldwide patents, product legal rights, and other miscellaneous intellectual residence from Innovative Facialdontics, LLC (“AFD”), a enterprise keeping propriety technology on sure Fda 510(k) cleared dental and medical devices.

With this asset obtain transaction, Vivos obtained U.S. patents, provisional patent applications as properly as Global patents, PCT patents and patent programs, so increasing its product or service portfolio and income prospective.

AFD’s flagship merchandise, the Preventive Oral System®, identified as the POD®, is a personalized solitary arch product with an Fda 510(k) clearance for managing an believed 40 million clients in the U.S. and Canada with Temporomandibular Joint Dysfunction (TMD) and/or Bruxism (enamel grinding or clenching), both recognised to be carefully related with OSA. Scientific studies have proven that there is a crystal clear link concerning OSA and TMD.

AFD’s next Fda 510(k) cleared product, acknowledged as the Night Block™, is a personalized twin-arch mandibular progression oral appliance that incorporates patented unilateral chunk block technologies, which can ease or eliminate several of the downsides of common oral appliance procedure these kinds of as inflammation of the TMJ, facial agony, neck soreness, headaches, tension, tiredness, clenching, and grinding.

The acquisition of these novel systems, patent portfolio and products legal rights further boost Vivos’ current intellectual property and technology base, enabling Vivos to give new, complementary items to a lot of OSA individuals who experience suffering, irritation, headaches, tooth reduction, and other indications involved with TMD and Bruxism.

In addition, this acquisition will deliver Vivos suppliers with an further treatment method choice for clients who do not have OSA, but endure from jaw soreness, complications, and daytime tiredness. Vivos expects to be capable to manufacture the AFD products and solutions by means of present manufacturing relationships.

Kirk Huntsman, Vivos’ Chairman and Main Government Officer, commented “This acquisition provides critical technological know-how and products that straight away open up new markets to us with important profits possible. We can now give dentists and clients a comprehensive line of decreased price items with bigger margins along with our current Vivos Method therapies to fulfill whatever scientific wants and economic price tag factors they might have to have. In this transaction, we have also acquired many U.S. and global patents, some of which were being granted in just the past couple of months that will let us to protect and shield our very first mover benefits in the U.S. and Canada as very well as other intercontinental markets. TMD and Bruxism are incredibly prevalent, but typically challenging to handle. We believe that this hugely helpful technological know-how from AFD is a authentic breakthrough, with substantial applications throughout several diverse sorts of current oral appliances, these kinds of as crystal clear aligners, palatal expanders, and regular mandibular advancement products, as perfectly as our individual Care equipment that are element of The Vivos Technique.”

In relationship with this transaction, Dr. Scott Simonetti, DDS, the founder and CEO of AFD and the inventor of the acquired patents, has been appointed as Vivos’ new Senior Director of Analysis and Products Progress. Dr. Simonetti reported, “I am elated to join the Vivos workforce with our company’s novel line of goods and engineering. Vivos is greatly regarded during the dental profession as a top provider of hugely successful treatment options through The Vivos Approach for specific debilitating disorders associated with breathing linked snooze ailments. I’m confident our latest and upcoming products will fit well into Vivos’ current technological innovation platform to supply a broad assortment of merchandise and providers to people who put up with from OSA.”

For more data, including transaction phrases, you should refer to Vivos’ Latest Report on Kind 8-K concerning this transaction that will be filed with the Securities and Trade Fee.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a professional medical technologies corporation targeted on producing and commercializing ground breaking diagnostic and therapy approaches for clients struggling from respiratory related snooze issues arising from specified dentofacial abnormalities these kinds of as gentle-to-reasonable obstructive sleep apnea (OSA) and snoring in older people. The Vivos Strategy signifies the initial clinically successful nonsurgical, noninvasive, nonpharmaceutical and price tag-effective remedy for treating gentle to reasonable OSA. It has established effective in somewhere around 31,000 patients dealt with throughout the world by extra than 1,650 educated dentists.

The Vivos Approach contains the Vivos Finish Airway Repositioning and/or Expansion (Care) equipment treatment and related protocols that change the measurement, shape and posture of the smooth tissues that comprise a patient’s upper airway and/or palate. The Vivos Technique opens airway room and may noticeably cut down signs and circumstances associated with moderate-to-reasonable OSA, such as decreasing Apnea Hypopnea Index scores. Vivos also marketplaces and distributes SleepImage diagnostic know-how below its VivoScore program for property snooze testing in older people and young children, as properly as the Preventive Oral Gadget®, known as the POD®, and the Evening Block™, every single of which are Fda accredited treatment options for Temporomandibular Joint Dysfunction (TMD) and/or Bruxism. The Vivos Built-in Observe (VIP) plan delivers dentists schooling and other benefit-extra products and services in link with employing The Vivos System.

For a lot more info, check out

Cautionary Notice Concerning Forward-On the lookout Statements

This press release and statements of the Company’s administration built in connection therewith have “forward-wanting statements” (as defined in Portion 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Trade Act of 1934, as amended) concerning long term situations, notably with respect to the community providing described herein. Phrases these types of as “may,” “should,” “expects,” “projects,” “intends,” “plans,” “believes,” “anticipates,” “hopes,” “estimates” and variations of this kind of words and phrases and identical expressions are supposed to recognize ahead-looking statements. These statements contain acknowledged and unidentified challenges and are dependent upon many assumptions and estimates, which are inherently subject matter to major uncertainties and contingencies, many of which are beyond Vivos’ regulate. Actual outcomes (together with, without having limitation, client demand for the obtained generated described herein and the impact of these products and solutions on the Company’s revenue and outcomes of Operations) may possibly differ materially from these expressed or implied by these types of ahead-seeking statements. Things that could result in true success to differ materially include, but are not limited to, the threat components explained in Vivos’ filings with the Securities and Trade Commission (“SEC”). Vivos’ filings can be obtained free of charge of cost on the SEC’s internet site at Apart from to the extent demanded by regulation, Vivos expressly disclaims any obligations or enterprise to release publicly any updates or revisions to any forward-hunting statements contained herein to replicate any alter in Vivos’ expectations with regard thereto or any transform in activities, problems, or circumstances on which any assertion is based mostly.

Vivos Trader Relations Contact:
Julie Gannon
Investor Relations Officer

Primary Logo

Source backlink